ARTICLE | Clinical News
AZ's selumetinib fails in Phase III uveal melanoma study
July 23, 2015 1:19 AM UTC
AstraZeneca plc (LSE:AZN; NYSE:AZN) said selumetinib plus dacarbazine missed the primary endpoint of progression-free survival (PFS) in the Phase III SUMIT study to treat metastatic uveal melanoma. The company said full analysis is ongoing; it did not release detailed data and did not respond to inquiries.
AZ licensed selumetinib from Array Pharmaceuticals Inc. (NASDAQ:ARRY) in 2003. In April, FDA granted the candidate Orphan Drug designation in uveal melanoma. ...